These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 17218037)

  • 21. Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy.
    Gelderblom HC; Zaaijer HL; Dijkgraaf MG; Van Der Meer J; Weegink CJ; Jansen PL; Beld MG; Reesink HW
    Scand J Gastroenterol; 2008; 43(7):857-69. PubMed ID: 18584525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic hepatitis C: management of treatment failures.
    Keeffe EB
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S102-5. PubMed ID: 16234055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
    Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
    Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
    Diago M; Castellano G; García-Samaniego J; Pérez C; Fernández I; Romero M; Iacono OL; García-Monzón C
    Gut; 2006 Mar; 55(3):374-9. PubMed ID: 16150856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
    Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
    Huang CF; Yeh ML; Hsieh MH; Hsieh MY; Lin ZY; Chen SC; Wang LY; Huang JF; Juo SH; Lin YC; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2013 Sep; 28(9):1515-20. PubMed ID: 23560893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.
    Gallegos-Orozco JF; Loaeza-del Castillo A; Fuentes AP; García-Sandoval M; Soto L; Rodríguez R; Gutiérrez-Ruíz MC; Gutiérrez-Reyes G; Bonder A; Olivera MA; Kershenobich D
    Liver Int; 2005 Feb; 25(1):91-5. PubMed ID: 15698404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
    Elefsiniotis IS; Vezali E; Mihas C; Saroglou G
    Intervirology; 2009; 52(5):247-51. PubMed ID: 19602898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.
    Brochot E; Riachi G; Plantier JC; Guillemard C; Vabret A; Mathurin P; Nguyen-Khac E; Duverlie G;
    J Med Virol; 2013 Jul; 85(7):1191-8. PubMed ID: 23918537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
    Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
    Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
    Aronsohn A; Ancuta I; Caruntu F; Coppola C; Delic D; Digiacomo A; Dusheiko GM; Lengyel G; Marcellin P; Orlandini A; Pruthi J; Silva GF; Tallarico L; Schmitz M; Tatsch F; Korner E; Cheinquer H
    J Viral Hepat; 2014 May; 21(5):377-80. PubMed ID: 24131506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices.
    Nomura H; Miyagi Y; Tanimoto H; Higashi M; Ishibashi H
    J Gastroenterol; 2009; 44(4):338-45. PubMed ID: 19277449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
    Yoshida EM; Sherman M; Bain VG; Cooper CL; Deschênes M; Marotta PJ; Lee SS; Krajden M; Witt-Sullivan H; Bailey RJ; Usaty C; Peltekian K;
    Can J Gastroenterol; 2009 Mar; 23(3):180-4. PubMed ID: 19319382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.